Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD3632 in Advanced Hematologic Malignancies (MOMENTUM)
jRCT2061250075Phase 1Recruiting
- Sponsor
- AstraZeneca
- Start
- Jun 2026
- Modality
- Small Molecules
01
Overview
Phase 1, open-label trial of AZD3632 in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (2 arms), sponsored by AstraZeneca. Primary endpoints: Dose-limiting toxicity (DLT) in Module 1, Dose modification, delay, and discontinuations due to adverse events (AEs) and 1 more. Started Jun 2026; status: recruiting.
02
Drugs
AZD3632
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on jRCT2061250075.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2061250075.